Selectikine (EMD 521873) / EMD Serono - LARVOL DELTA

A targeted modified IL-2 (NHS-IL2) combined with stereotactic body radiation therapy (SBRT) in patients with advanced melanoma refractory to checkpoint inhibitors: Results from a Phase IIa trial (SITC 2018) - P2; "Conclusions NHS-IL2 combined with SBRT had acceptable safety and tolerability, and demonstrated disease control in heavily pretreated patients with advanced melanoma who failed ipilimumab +/- anti-PD1 without the toxicities often associated with IL-2 treatment. Further evaluation of NHS-IL2, including combination with immune checkpoint inhibitors, may be warranted."

Checkpoint inhibition • Clinical • IO biomarker • P2a data • PD(L)-1 Biomarker • Melanoma